Karuna Therapeu Stock
StockStockPrice
Frequently asked questions
What is Karuna Therapeu's market capitalization?
What is the Earnings Per Share (EPS) for Karuna Therapeu?
What are the analyst ratings and target price for Karuna Therapeu's stock?
What is Karuna Therapeu's revenue over the trailing twelve months?
What is the EBITDA for Karuna Therapeu?
What is the free cash flow of Karuna Therapeu?
What is the 5-year beta of Karuna Therapeu's stock?
How many employees does Karuna Therapeu have, and what sector and industry does it belong to?
What is the free float of Karuna Therapeu's shares?
Financials
Market Cap
$12.58B5Y beta
1.15EPS (TTM)
-$11.73Free Float
35.32MRevenue (TTM)
$654.00KEBITDA (TTM)
-$493.08MFree Cashflow (TTM)
-$388.74MPricing
Analyst Ratings
The price target is $322.67 and the stock is covered by 17 analysts.
Buy
1
Hold
15
Sell
1
Information
Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its pipeline built on the therapeutic potential of its lead product candidate, KarXT (xanomeline-trospium), an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. KarXT combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS. It is developing KarXT for the treatment of acute psychosis in adults with schizophrenia, and for the treatment of psychosis in Alzheimer's disease. Its pipeline also includes clinical-stage candidate KAR-2618, a TRPC4/5 inhibitor for the treatment of mood and anxiety disorders, and pre-clinical muscarinic, TRPC4/5 and target-agnostic compounds for the treatment of psychiatric and neurological conditions.
339
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker